We are live on ! Find out more

Evogene

EVGN

Market cap $7.32M

0.4630 USD

-0.0360

7.21%

At close Updated Sep 21, 4:00 PM EDT

Pre-market

After hours

0.4620

-0.0010

0.22%

1 day

-7.21%

5 days

-3.74%

1 month

-17.69%

3 months

-7.21%

6 months

-50.47%

Year to date

-59.03%

1 year

-60.43%

5 years

-98.38%

10 years

-99.29%

About: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.

Employees: 52

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A.

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareholders (“AGM”) held on August 25, 2026. A total of 16,172,472 common shares were represented at the meeting, representing 62.43% of the Company's outstanding shares. The following is a summary of the proxy voting results for the AGM. 1. Election of Directors The following individuals were elected as.

EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis have recommended that Evogene shareholders vote "FOR" the Company slate of nominees in connection with the September 4, 2026 Annual General Meeting of Shareholders.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

Evogene Reports Second Quarter and First Half 2026 Financial Results

Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024 Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025 and approximately $6.0 million in the second quarter of 2024 Six active drug development collaborations established with biotechnology companies and leading academic institutions Virtual chemical space expanded to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents REHOVOT, Israel, Aug. 18, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first half of 2026 and second quarter ended June 30, 2026, and provided an update on its strategic and operational progress.

Evogene Reports Second Quarter and First Half 2026 Financial Results

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that its Chairman, Nir Nimrodi, will join the Company's upcoming quarterly results conference call on August 18, 2026.

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Schedules Second Quarter 2026 Financial Results Release

Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the second quarter 2026, on Tuesday , August 18 , 2026.

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July 22, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and ELEO Inc., a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

See News Rankings

Price charts implemented using Lightweight Charts™